期刊
CANCERS
卷 7, 期 3, 页码 1815-1846出版社
MDPI
DOI: 10.3390/cancers7030864
关键词
non-small cell lung cancer (NSCLC); epidermal growth factor receptor (EGFR); anaplastic lymphoma kinase (ALK); tyrosine kinase inhibitors; immuno-oncology; cytotoxic T lymphocyte antigen-4 (CTLA-4); programmed death-1 receptor (PD-1); PD-1 inhibitors
类别
资金
- Petre Foundation
- National Health and Medical Research Council of Australia [GNT1048669, 0546204, 0546098]
- Cancer Council of NSW [RG15-17]
- Victorian Government's Operational Infrastructure Support Program
- Victorian Cancer Agency
The landscape of advanced non-small lung cancer (NSCLC) therapies has rapidly been evolving beyond chemotherapy over the last few years. The discovery of oncogenic driver mutations has led to new ways in classifying NSCLC as well as offered novel therapeutic targets for anticancer therapy. Targets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) gene rearrangements have successfully been targeted with appropriate tyrosine kinase inhibitors (TKIs). Other driver mutations such as ROS, MET, RET, BRAF have also been investigated with targeted agents with some success in the early phase clinical setting. Novel strategies in the field of immune-oncology have also led to the development of inhibitors of cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed death-1 receptor (PD-1), which are important pathways in allowing cancer cells to escape detection by the immune system. These inhibitors have been successfully tried in NSCLC and also now bring the exciting possibility of long term responses in advanced NSCLC. In this review recent data on novel targets and therapeutic strategies and their future prospects are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据